Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

Miller, 2004, Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer, J Clin Oncol, 22, 1103, 10.1200/JCO.2004.08.158 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Pao, 2004, EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and correlate with sensitivity of tumors to gefitinib (Iressa) and erlotinib (Tarceva), Proc Natl Acad Sci USA, 101, 13306, 10.1073/pnas.0405220101 Sequist, 2006, Epidermal growth factor receptor mutation testing in the care of lung cancer patients, Clin Cancer Res, 12, 4403s, 10.1158/1078-0432.CCR-06-0099 Shih, 2006, Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer, Int J Cancer, 118, 963, 10.1002/ijc.21458 Marchetti, 2006, Assessing EGFR mutations, N Engl J Med, 354, 526, 10.1056/NEJMc052564 Morikawa, 2006, Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan, J Clin Oncol (Meeting Abstracts), 24, 7077, 10.1200/jco.2006.24.18_suppl.7077 Paz-Ares, 2006, A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR), J Clin Oncol (Meeting Abstracts), 24, 7020, 10.1200/jco.2006.24.18_suppl.7020 Sunaga, 2006, Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations, J Clin Oncol (Meeting Abstracts), 24, 7183, 10.1200/jco.2006.24.18_suppl.7183 Sutani, 2006, Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp, Br J Cancer, 95, 1483, 10.1038/sj.bjc.6603466 Inoue, 2006, Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations, J Clin Oncol, 24, 3340, 10.1200/JCO.2005.05.4692 Kris MG, Pao W, Zakowski MF, et al. Prospective trial with preoperative genfitinib to correlate lung cancer response with EGFR exon 19 and 21 mutations and to select patients for adjuvant therapy. ASCO (Meeting Abstracts). 2006. Marks JL, Broderick S, Zhou Q, et al. Prognostic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (in press). Toyooka, 2006, Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung, Int J Cancer, 118, 1588, 10.1002/ijc.21500 Zakowski, 2006, EGFR mutations in small-cell lung cancers in patients who have never smoked, N Engl J Med, 355, 213, 10.1056/NEJMc053610 Morinaga, 2007, Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation, Lung Cancer, 58, 411, 10.1016/j.lungcan.2007.05.014 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022 Blons, 2006, Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation, Am J Surg Pathol, 30, 1309, 10.1097/01.pas.0000213285.65907.31 Ebright, 2002, Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma, Ann Thorac Surg, 74, 1640, 10.1016/S0003-4975(02)03897-3 Sakuma, 2007, Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung, Mod Pathol, 20, 967, 10.1038/modpathol.3800929 Johnson, 2005, Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations?, J Clin Oncol, 23, 6813, 10.1200/JCO.2005.97.008 Kaye, 2005, A curious link between epidermal growth factor receptor amplification and survival: effect of ‘allele dilution’ on gefitinib sensitivity?, J Natl Cancer Inst, 97, 621, 10.1093/jnci/dji127 Bunn, 2006, Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy, Clin Cancer Res, 12, 3652, 10.1158/1078-0432.CCR-06-0261 Li AR, Chitale DA, Riely GJ, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn (in press). Takano, 2005, Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer, J Clin Oncol, 23, 6829, 10.1200/JCO.2005.01.0793 Miller V, Riely GJ, Zakowski M, et al. Molecular characteristics of bronchioalvelor carcinoma and adenocarcinoma BAC subtype predict response to erlotinib. J Clin Oncol (in press). Endo, 2006, Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy, Oncol Rep, 16, 533 Han, 2006, Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation, Clin Cancer Res, 12, 2538, 10.1158/1078-0432.CCR-05-2845 Ichihara, 2007, The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer, Int J Cancer, 120, 1239, 10.1002/ijc.22513 Cappuzzo, 2005, Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer, J Natl Cancer Inst, 97, 643, 10.1093/jnci/dji112 Riely, 2006, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib, Clin Cancer Res, 12, 839, 10.1158/1078-0432.CCR-05-1846 Jackman, 2006, Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib, Clin Cancer Res, 12, 3908, 10.1158/1078-0432.CCR-06-0462 Marchetti, 1996, Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype, J Pathol, 179, 254, 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J Marchetti, 2005, EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment, J Clin Oncol, 23, 857, 10.1200/JCO.2005.08.043 Parra, 2004, Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer, Br J Cancer, 91, 208, 10.1038/sj.bjc.6601923 Pan, 2005, Rapid PCR-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas, J Mol Diagn, 7, 396, 10.1016/S1525-1578(10)60569-7 Asano, 2006, Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay, Clin Cancer Res, 12, 43, 10.1158/1078-0432.CCR-05-0934 Sasaki, 2005, EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler, Clin Cancer Res, 11, 2924, 10.1158/1078-0432.CCR-04-1904 Zhou, 2006, Rapid detection of epidermal growth factor receptor mutations in non-small cell lung cancer using real-time polymerase chain reaction with TaqMan-MGB probes, Cancer J, 12, 33, 10.1097/00130404-200601000-00007 Janne, 2006, A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening, Clin Cancer Res, 12, 751, 10.1158/1078-0432.CCR-05-2047 Cohen, 2006, Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer, Cancer, 107, 2858, 10.1002/cncr.22331 Thomas, 2006, Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing, Nat Med, 12, 852, 10.1038/nm1437 Pao, 2007, Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method, Clin Cancer Res, 13, 4954, 10.1158/1078-0432.CCR-07-1387 Soung, 2005, Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas, Virchows Arch, 446, 483, 10.1007/s00428-005-1254-y Shigematsu, 2005, Somatic mutations of the HER2 kinase domain in lung adenocarcinomas, Cancer Res, 65, 1642, 10.1158/0008-5472.CAN-04-4235 Buttitta, 2006, Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features, Int J Cancer, 119, 2586, 10.1002/ijc.22143 Yokoyama, 2006, EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification, Cancer Sci, 97, 753, 10.1111/j.1349-7006.2006.00233.x Marks, 2007, Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4, PLoS ONE, 2, e426, 10.1371/journal.pone.0000426 Sonobe, 2006, Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain, J Mol Diagn, 8, 351, 10.2353/jmoldx.2006.050132 Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLos Med, 2, e17, 10.1371/journal.pmed.0020017 Eberhard, 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib, J Clin Oncol, 23, 5900, 10.1200/JCO.2005.02.857 Massarelli, 2007, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer, Clin Cancer Res, 13, 2890, 10.1158/1078-0432.CCR-06-3043 Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma (submitted). Solit, 2006, BRAF mutation predicts sensitivity to MEK inhibition, Nature, 439, 358, 10.1038/nature04304 Pao, 2005, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, 2, e73, 10.1371/journal.pmed.0020073 Kobayashi, 2005, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, 352, 786, 10.1056/NEJMoa044238 Balak, 2006, Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors, Clin Cancer Res, 12, 6494, 10.1158/1078-0432.CCR-06-1570 Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res, 12, 5764, 10.1158/1078-0432.CCR-06-0714 Engelman, 2006, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest, 116, 2695, 10.1172/JCI28656 Inukai, 2006, Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer, Cancer Res, 66, 7854, 10.1158/0008-5472.CAN-06-1951 Bell, 2005, Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR, Nat Genet, 37, 1315, 10.1038/ng1671 Vikis, 2007, EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity, Cancer Res, 67, 4665, 10.1158/0008-5472.CAN-07-0217 Engelman, 2007, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling, Science, 316, 1039, 10.1126/science.1141478 Bean, 2007, MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib and erlotinib, Proc Natl Acad Sci USA, 104, 20932, 10.1073/pnas.0710370104 Birchmeier, 2003, Met, metastasis, motility and more, Nat Rev Mol Cell Biol, 4, 915, 10.1038/nrm1261 Cappuzzo, 2004, Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer, J Natl Cancer Inst, 96, 1133, 10.1093/jnci/djh217 Han, 2005, Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer, Int J Cancer, 113, 109, 10.1002/ijc.20550 Han, 2005, Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib, J Clin Oncol, 23, 2493, 10.1200/JCO.2005.01.388 Sonobe, 2007, Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer, J Surg Oncol, 95, 63, 10.1002/jso.20547 Yauch, 2005, Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients, Clin Cancer Res, 11, 8686, 10.1158/1078-0432.CCR-05-1492 Coldren, 2006, Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines, Mol Cancer Res, 4, 521, 10.1158/1541-7786.MCR-06-0095 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945